ReviewPharmacology research & perspectives2015

Preclinical pharmacology and pharmacokinetics of CERC-301, a GluN2B-selective N-methyl-D-aspartate receptor antagonist.

Rachel Garner et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.